ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Daiichi Sankyo Co Ltd (PK)

Daiichi Sankyo Co Ltd (PK) (DSKYF)

31.55
3.01
(10.56%)
마감 20 11월 6:00AM

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

가격
31.55
매수가
28.90
매도가
31.55
거래량
7,288
28.15 일간 변동폭 31.55
25.95 52주 범위 44.64
market_cap
전일 종가
28.536
개장가
28.31
최근 거래 시간
51
@
30.525
마지막 거래 시간
재정 규모
US$ 216,759
VWAP
29.742
평균 볼륨(3m)
3,463
발행 주식
1,916,787,029
배당수익률
14,716.64%
주가수익률
0.30
주당순이익(EPS)
104.72
매출
1.63T
순이익
200.73B

Daiichi Sankyo Co Ltd (PK) 정보

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Biolog/vaccines
본부
Chuo, Tokyo, Jpn
설립됨
2005
Daiichi Sankyo Co Ltd (PK) is listed in the Pharmaceutical Preparations sector of the OTC 시장 with ticker DSKYF. The last closing price for Daiichi Sankyo (PK) was US$28.54. Over the last year, Daiichi Sankyo (PK) shares have traded in a share price range of US$ 25.95 to US$ 44.64.

Daiichi Sankyo (PK) currently has 1,916,787,029 shares in issue. The market capitalisation of Daiichi Sankyo (PK) is US$54.70 billion. Daiichi Sankyo (PK) has a price to earnings ratio (PE ratio) of 0.30.

DSKYF 최신 뉴스

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular ...

Daiichi Sankyo's Once-Daily Lixiana® (edoxaban) Approved for the Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent...

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge

Daiichi Sankyo, Inc. and Asubio Pharmaceuticals, Inc. Merge PR Newswire PARSIPPANY, N.J., April 1, 2015 PARSIPPANY, N.J., April 1, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc., the US subsidiary of...

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources

Daiichi Sankyo, Inc. Names Danesha Dixon Smith Vice President of Human Resources PR Newswire PARSIPPANY, N.J., June 28, 2011 PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc...

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc.

John P. Gargiulo Named President and CEO of Daiichi Sankyo, Inc. PR Newswire PARSIPPANY, N.J., April 4, 2011 PARSIPPANY, N.J., April 4, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced...

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fib

Update: Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest...

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillatio

Daiichi Sankyo Completes Enrollment of the Edoxaban Global Phase III ENGAGE AF-TIMI 48 Study in Patients With Atrial Fibrillation - More Than 21,000 Patients Enrolled in the Largest Clinical...

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology

ArQule and Daiichi Sankyo Expand Drug Discovery Collaboration in Oncology PR Newswire WOBURN, Massachusetts, October 12, 2010 WOBURN, Massachusetts, October 12, 2010 /PRNewswire/ -- ArQule, Inc...

Patients with Hypertension at Risk Due to Physician Inertia

Patients with Hypertension at Risk Due to Physician Inertia - New Supporting Hypertension Awareness and Research Europe-wide (SHARE) Survey Reports Findings at the 20th Annual Society of the...

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban

Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban - Innovative Once-Daily Oral Factor Xa Inhibitor Submitted for Approval in Japan PR Newswire TOKYO, April...

Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs

Bolsters Company's Expertise in Areas of Oncology and Hematology PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D...

기간변동변동 %시가고가저가평균 일일 거래량VWAP
11.093.5784635587730.4633.0927.15674828.91900714CS
40.391.2516046213131.1634.627.15457830.91492183CS
12-6.89-17.92403746138.4444.6427.15346333.52745314CS
26-4.33-12.068004459335.8844.6427.15549334.50607706CS
524.9918.787650602426.5644.6425.951019631.65880671CS
1564.7217.592247484226.8344.6419.45802030.16840193CS
260-30.529411-49.177997194662.07941195.9617.61618930.10797516CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
PDROPedros List Inc (CE)
US$ 0.0032
(319,900.00%)
31.17k
GBXIGBX International Group Inc (CE)
US$ 0.0002
(19,900.00%)
1.53k
TTCFQTattooed Chef Inc (CE)
US$ 0.0001
(9,900.00%)
54.21k
MGTIMGT Capital Investments Inc (CE)
US$ 0.0001
(9,900.00%)
457.82k
ATHCAccelerated Technologies Holding Corporation (CE)
US$ 0.0001
(9,900.00%)
173
AGDXFAntioqua Gold Inc (CE)
US$ 0.000001
(-100.00%)
60k
FGHFFForte Group Holdings Inc (PK)
US$ 0.0007
(-99.82%)
343
IGFFFInfinito Gold Ltd (CE)
US$ 0.000001
(-99.80%)
15k
EGRNFChina Evergrande Group (CE)
US$ 0.000001
(-99.67%)
500
LLBOLifeline Biotech Inc (CE)
US$ 0.000001
(-99.67%)
1.01M
NSAVNet Savings Link Inc (PK)
US$ 0.00105
(31.25%)
173.45M
RDARRaadr Inc (PK)
US$ 0.0008
(33.33%)
172.18M
AITXArtificial Intelligence Technology Solutions Inc (PK)
US$ 0.0035
(2.94%)
165.17M
HMBLHUMBL Inc (PK)
US$ 0.0003
(0.00%)
146.21M
CBDLCBD Life Sciences Inc (PK)
US$ 0.0005
(25.00%)
125.1M

최근 히스토리

Delayed Upgrade Clock